Aarti Drugs Share Price

NSE
AARTIDRUGS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Aarti Drugs
Aarti Drugs Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Aarti Drugs Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
Near 52W Low of ₹330.05
-24.4
Dividend yield 1yr %
Below industry Median
0.3

Aarti Drugs Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Aarti Drugs Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
556.6 Cr
598.33 Cr
555.34 Cr
619.99 Cr
605.94 Cr

Aarti Drugs Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
2532.61 Cr
2718.25 Cr
2499.96 Cr
2159.3 Cr
1807.57 Cr

Aarti Drugs Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
37.09 Cr
34.96 Cr
33.27 Cr
47.31 Cr
36.71 Cr

Aarti Drugs Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
171.59 Cr
166.36 Cr
205 Cr
280.4 Cr
141.4 Cr
Aarti Drugs Result Highlights
  • Aarti Drugs Ltd reported a 5.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 6.4%.

  • Its expenses for the quarter were down by 6.5% QoQ and 6.9% YoY.

  • The net profit increased 6.1% QoQ and increased 1.0% YoY.

  • The earnings per share (EPS) of Aarti Drugs Ltd stood at 4.1 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Aarti Drugs shareholding Pattern

Promoter
55.4%
Foreign Institutions
2.3%
Mutual Funds
7.8%
Domestic Institutions
8.7%
Public
33.6%
Promoter
55.6%
Foreign Institutions
2.5%
Mutual Funds
6.2%
Domestic Institutions
7.8%
Public
34%
Promoter
55.7%
Foreign Institutions
3%
Mutual Funds
5.7%
Domestic Institutions
7.3%
Public
34%
Promoter
57.1%
Foreign Institutions
2.6%
Mutual Funds
5.1%
Domestic Institutions
6%
Public
34.3%
Promoter
57.5%
Foreign Institutions
2.1%
Mutual Funds
5.2%
Domestic Institutions
5.3%
Public
35.2%
Promoter
58.6%
Foreign Institutions
2.3%
Mutual Funds
5.2%
Domestic Institutions
5.3%
Public
33.8%

Aarti Drugs Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
345.20
10Day EMA
347.80
12Day EMA
349.10
20Day EMA
355.00
26Day EMA
359.90
50Day EMA
379.30
100Day EMA
410.70
200Day EMA
444.30
5Day SMA
345.60
10Day SMA
347.50
20Day SMA
351.20
30Day SMA
362.20
50Day SMA
381.60
100Day SMA
417.60
150Day SMA
453.00
200Day SMA
470.40
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
157031 Rs
283935 Rs
Week Rs
180931 Rs
376852 Rs
Month Rs
110694 Rs
234205 Rs
Resistance & Support
346.17
Pivot
Resistance
First Resistance
354.13
Second Resistance
367.97
Third Resistance
375.93
Support
First Support
332.33
Second support
324.37
Third Support
310.53
Relative Strength Index
41.66
Money Flow Index
41.51
MACD
-10.87
MACD Signal
-12.10
Average True Range
16.49
Average Directional Index
16.48
Rate of Change (21)
-8.72
Rate of Change (125)
-33.84

Aarti Drugs Company background

Founded in: 1984
Managing director: Rashesh C Gogri
Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, AntiInflammatory, Antidiabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a whollyowned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two RD divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 199495, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company.During the year 199697, the company started their production of secnidazole and dichlofenac sodium. During the year 200001, they started the commercial production of Pharmaceutical Ingredients. During the year 200203, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg. During the year 200304, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 200405, the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 200506, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.During the year 200607, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 200809, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg.During the year 200910, the company carried out process improvement work in bulk drugs, such as antihistaminic/antiallergic, antiinflammatory and antidiabetic. ADL expanded the production capacity from 25,000,000 kg to 25,716,000 kg. A Scheme of Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary of the Company, with the Company became operative w.e.f. from 6th July, 2012.During year 2015, Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd., situated at Baddi, Himachal Pradesh. During year 2020, Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA, incorporated in Santiago, Chile, was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary), in Mumbai, was carrying on business of manufacturers, producers, processors, buyers, sellers, importers, exporters or otherwise dealers in Speciality and other chemicals, pharmaceutical and drugs. In 2022, the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur, which turned operational effective from May 2022.
Read More

Aarti Drugs FAQs

Aarti Drugs share price is ₹340.3 in NSE and ₹339.8 in BSE as on 27/3/2025.

Aarti Drugs share price in the past 1-year return was -21.64. The Aarti Drugs share hit a 1-year low of Rs. 330.05 and a 1-year high of Rs. 635.

The market cap of Aarti Drugs is Rs. 3128.55 Cr. as of 27/3/2025.

The PE ratios of Aarti Drugs is 23.68 as of 27/3/2025.

The PB ratios of Aarti Drugs is 2.69 as of 27/3/2025

The Mutual Fund Shareholding in Aarti Drugs was 7.78% at the end of 27/3/2025.

You can easily buy Aarti Drugs shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Aarti Drugs stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -